OncoGenesis addresses the tremendous, unmet clinical need for an easy-to-use and accurate screening of women for cervical cancer. The company offers a comprehensive solution ranging from optimal specimen collection to point-of-care diagnostic testing, setting a new standard of care for diagnosing and treating cervical cancer worldwide. Our goal is to provide a solution that clinically outperforms existing screening technologies in a cost-effective format that can be run anywhere globally, including resource-limited regions of the world where the problem of cervical cancer is a healthcare crisis. To accomplish this, OncoGenesis has developed a useful self-collection device, iPap, that allows women to obtain their cervical specimens in the privacy of their homes. The company is also developing the CerMark multiplex biomarker test that measures the critical cellular changes in a cervical tissue specimen to detect cervical cancer and its progression. The CerMark test will be available first on a laboratory-based system (LAB) and then on our Point-of-Care (POC) device.